Drug intelligence / Profile preview

IMB217P

Development stage: Preclinical
Lead developer: ImmunoBiochem
Modality: Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous, Intramuscular, Inhalation, Intranasal, Intradermal, Intrathecal, Intraarticular, Intratumoral, Intralesional, Intraperitoneal, Parenteral

Overview

IMB217P is a first-in-class degrader-antibody conjugate (DAC) developed by ImmunoBiochem. It is designed to target an undisclosed integrin for the treatment of diseases associated with mucosal immunity. The therapeutic combines the high selectivity of a monoclonal antibody with a degrader payload, a modality intended to achieve targeted protein degradation (TPD) within specific cell populations. As of mid-2026, the program is in the IND-enabling stage of development.

Targets

Neuraminidase

Beyond the preview

Go deeper on IMB217P.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMB217P.

Explore the full profile